Inhibrx Biosciences, Inc. INBX Business Segments — Other Research and Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.
The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s business segments — other research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s business segments — other research and development expense?
- Inhibrx Biosciences, Inc. (INBX) reported business segments — other research and development expense of $2.91M in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s business segments — other research and development expense changed year-over-year?
- Inhibrx Biosciences, Inc.'s business segments — other research and development expense decreased by 7.8% year-over-year, from $3.15M to $2.91M.
- What does business segments — other research and development expense mean?
- This metric encompasses miscellaneous research and development costs not categorized under clinical trials, personnel, or manufacturing. It typically includes laboratory supplies, software licenses, and external consulting fees related to scientific research. It provides visibility into the ancillary costs necessary to support the broader R&D ecosystem.